Doxercalciferol - Moligand™, 10mM in DMSO , Vitamin D receptor agonist, CAS No.54573-75-0, Vitamin D receptor agonist

CAS: 54573-75-0 Cat. No.: D408749 Molecular Weight: 412.65 EC Number: 643-005-9 PubChem CID: 5281107

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

1α-hydroxyvitamin D2 | (1R,3S,E)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyl-octahydroinden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Doxercalciferol (1α-hydroxyvitamin D2) is a syntheticvitamin D2analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.
In vitro

In vivo

Doxercalciferol (100 or 300 pg/g b.w.) normalizes serum calcium and parathyroid hormone (PTH) levels in nephrectomy treated mice. Doxercalciferol (300 pg/g b.w.) significantly reduces osteitis fibrosa in nephrectomy treated mice. Doxercalciferol results in significant decrease in cardiac hypertrophy and improves cardiac function in rats fed a high salt (HS) diet. Doxercalciferol treatment leads to a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level in rats fed a high salt (HS) diet. Doxercalciferol also significantly reduces the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency. Doxercalciferol decreases proteinuria, podocyte injury, mesangial expansion, and extracellular matrix protein accumulation in Diet-induced obesity (DIO) mice. Doxercalciferol also decreases macrophage infiltration, oxidative stress, proinflammatory cytokines, and profibrotic growth factors in DIO mice. Doxercalciferol also prevents the activation of the renin-angiotensin-aldosterone system including the angiotensin II type 1 receptor and the mineralocorticoid receptor in DIO mice. Doxercalciferol combined with Losartan most effectively prevents albuminuria, restored glomerular filtration barrier structure, and dramatically reduces glomerulosclerosis in a dose-dependent manner in mice. Doxercalciferol combined with Losartan virtually prevents morphological and molecular changes in diabetic kidneys of mice.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Synonyms

1α-hydroxyvitamin D2 | (1R, 3S, E)-5-((E)-2-((1R, 3aS, 7aR)-1-((2R, 5S, E)-5, 6-dimethylhept-3-en-2-yl)-7a-methyl-octahydroinden-4-ylidene)ethylidene)-4-methylenecyclohexane-1, 3-diol

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

Doxercalciferol (1α-hydroxyvitamin D2) is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

AGONIST

Mechanism of action

Vitamin D receptor agonist

Product Properties

• ALogP: 6.3

Names and Identifiers

• Isomeric SMILES: C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C
• WGK Germany: 3
• PubChem CID: 5281107
• Molecular Weight: 412.65

Associated Targets(Human)

VDR Tclin Vitamin D3 receptor (0 Activities)

Discover Target: VDR

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Chemical and Physical Properties

• Melt Point(°C): 140 °C